CleanGo Innovations Inc. Subsidiary, Kubera Black, Concludes Due Diligence; Decides Against Acquisition of Freia Farmaceutici Srl

Executive Summary

• CleanGo Innovations Inc. and its subsidiary Kubera Black have decided not to proceed with the previously announced acquisition of Freia Farmaceutici Srl.
• The termination follows extensive due‑diligence and a strategic assessment that the target does not meet the company’s high‑growth, capital‑efficient model.
• The decision preserves CleanGo’s capital position and allows focus on higher‑growth assets in its pipeline.

Key Details

• Original Announcement: Non‑binding LOI with Freia Farmaceutici Srl disclosed on 2025‑12‑17.
• Decision Date: March 9, 2026 – after a comprehensive evaluation period.
• Strategic Rationale:
• Growth Alignment: Freia Farmaceutici did not meet the specific high‑growth targets set by CleanGo’s board.
• Resource Allocation: Projected time and capital required were deemed excessive given competitive landscape.
• Asset Prioritization: Company will prioritize assets offering more immediate fit for global expansion.
• Management Commentary: Leadership emphasized that the decision is based solely on internal growth criteria, not on any deficiency of Freia Farmaceutici.
• Future Outlook: CleanGo remains committed to a disciplined acquisition strategy, focusing on higher‑growth opportunities within its pipeline while preserving capital and executive bandwidth.

Notable Quotes

“We want to be clear that our decision is strictly based on our internal high‑growth model and investment criteria,” said the leadership team at CleanGo Innovations.
“There is nothing inherently wrong with Freia Farmaceutici Srl; they are a professional organization, but the project simply required too much time and capital to bring forward for a global launch at this stage.”